TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12886798

Group type: EXPERIMENTAL
Intervention: Community-based participatory intervention
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28000
Study: 10233190

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) and two antibiotics (metronidazole, tetracycline) twice daily for 14 days
Number of subjects: 50
Study: 7793406

Group type: EXPERIMENTAL
Intervention: Upright exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supine exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest (supine and upright)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rest (hypertensive patients)
Number of subjects: 20
Study: 2405730

Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Penrose drains
Number of subjects: 370

Group type: COMPARATOR
Intervention: No drains
Number of subjects: 370
Study: 7418351

Group type: EXPERIMENTAL
Intervention: Metoclopramide (Primperan) administration prior to examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Metoclopramide)
Number of subjects: 0
Study: 6149595

Group type: EXPERIMENTAL
Intervention: Fluperlapine (200-600 mg/day)
Number of subjects: 11
Study: 29696812

Group type: EXPERIMENTAL
Intervention: Moderate-to-high-intensity aerobic and resistance exercise intervention (20 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Home-based exercise of light intensity (control group)
Number of subjects: 74
Study: 29878947

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with rocuronium and reversed with sugammadex
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 34
Study: 27028731

Group type: EXPERIMENTAL
Intervention: Darker backgrounds (black)
Number of subjects: 100
Study: 24824548

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 3234
Study: 22301884

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/wk
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mipomersen 300 mg/wk
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg/wk
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mipomersen (100, 200, 300 mg/wk)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19655226

Group type: EXPERIMENTAL
Intervention: Fleet ready‐to‐use enema
Number of subjects: 203

Group type: COMPARATOR
Intervention: Glycerin suppositories
Number of subjects: 203
Study: 16762570

Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF) after PRF
Number of subjects: 40
Study: 15917051

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in practices in the most deprived tertile
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in the mid SMR tertile
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in the highest SMR tertile
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in individuals with poorer quality housing
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in married individuals or those with respiratory conditions
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Influenza vaccination in individuals who smoked, had cognitive impairment, or depression
Number of subjects: 5572
Study: 12394530

Group type: EXPERIMENTAL
Intervention: RUL ECT at eight times seizure threshold (ST)
Number of subjects: 77

Group type: COMPARATOR
Intervention: BL ECT at 1.5 times seizure threshold (ST)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RUL ECT at eight times ST
Number of subjects: 77

Group type: COMPARATOR
Intervention: BL ECT at 1.5 times ST
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both RUL ECT and BL ECT
Number of subjects: 77
Study: 10462868

Group type: EXPERIMENTAL
Intervention: Emergency department protocol for the identification and acute management of abused women; staff training in protocol use.
Number of subjects: 10961
Study: 7885820

Group type: EXPERIMENTAL
Intervention: Extended haptic perception of gap size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulated rotational inertia of the probe
Number of subjects: 0
Study: 2229524

Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% cream
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 27
Study: 338872

Group type: EXPERIMENTAL
Intervention: Intramuscular iron treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31854285

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up (ABC) intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 23
Study: 31808278

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: PRP (Panretinal photocoagulation)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined ranibizumab 0.5 mg/PRP
Number of subjects: 106
Study: 29110753

Group type: EXPERIMENTAL
Intervention: Upright position during second-stage labour
Number of subjects: 3236

Group type: COMPARATOR
Intervention: Lying-down position during second-stage labour
Number of subjects: 3236

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 3236

Group type: COMPARATOR
Intervention: Lying-down position
Number of subjects: 3236
Study: 25938711

Group type: EXPERIMENTAL
Intervention: High-absorbency disposable diapers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional low-absorbency cloth diapers
Number of subjects: 0
Study: 23816967

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day
Number of subjects: 345

Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 345
Study: 22866006

Group type: EXPERIMENTAL
Intervention: Endotoxin (20 IU/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vaccination against Salmonella typhi
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study: 18752281

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study: 17531723

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.2% ropivacaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with meperidine
Number of subjects: 56
Study: 15465984

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 10759649

Group type: EXPERIMENTAL
Intervention: N-butyl-2-cyanoacrylate (Tisuacryl)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 130
Study: 8825534

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study: 1488694

Group type: COMPARATOR
Intervention: ORS (30 cases)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ORS and Smectite (3.6 g/day) (32 cases)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ORS and Smectite (3.6 g/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 3003729

Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study: 31904175

Group type: EXPERIMENTAL
Intervention: Oral hydrolyzed eggshell membrane (450 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29789130

Group type: EXPERIMENTAL
Intervention: Red wine (300 ml/day for men, 230 ml/day for women)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline comparison with healthy volunteers
Number of subjects: 24
Study: 28316276

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 μg/kg/min for 1 hour, followed by 0.1 μg/kg/min for 23 hours)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 849

Group type: COMPARATOR
Intervention: Levosimendan and Placebo
Number of subjects: 849
Study: 26179377

Group type: EXPERIMENTAL
Intervention: Evening-before regimen of sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Same-day regimen of sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Evening-before polyethylene glycol (PEG)
Number of subjects: 490
Study: 23176401

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration (OHDF)
Number of subjects: 24
Study: 21765345

Group type: EXPERIMENTAL
Intervention: Amifostine (10-100 mg/kg, intraperitoneal injection)
Number of subjects: 100
Study: 18506008

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ambrisentan monotherapy
Number of subjects: 394
Study: 16805144

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Acclimatization in the pretrial week
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Slower ascent rate
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rest days
Number of subjects: 400
Study: 14555501

Group type: EXPERIMENTAL
Intervention: Measuring six lesions bidimensionally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Measuring four lesions undimensionally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Measuring six or more lesions bidimensionally
Number of subjects: 36
Study: 10617696

Group type: EXPERIMENTAL
Intervention: Intubation and suctioning (INT)
Number of subjects: 2094

Group type: COMPARATOR
Intervention: Expectant management (EXP)
Number of subjects: 2094
Study: 1390316

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin 400 mg/m2 day 1 and 5-FU 1 g/m2/d as a continuous infusion days 1 through 5 every 3 weeks, given to 108 patients.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (not specified as control).
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (locoregional treatment alone).
Number of subjects: 219
Study: 3888433

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tamoxifen with aminoglutethimide
Number of subjects: 66
Study: 31120943

Group type: EXPERIMENTAL
Intervention: Influenza vaccination (inactivated quadrivalent influenza vaccine)
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 1838
Study: 30428847

Group type: EXPERIMENTAL
Intervention: Adefovir (ADV)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: TDF plus LMV
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 26517576

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) + β-blocker
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 72
Study: 24092275

Group type: EXPERIMENTAL
Intervention: CISTIMEV PLUS(®), 1 tablet daily for 30 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 83
Study: 22107835

Group type: EXPERIMENTAL
Intervention: Xiaozhang Tie (traditional Chinese herbal cataplasm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Xiaozhang Tie
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20829648

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Recording (keeping a diary)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 399
Study: 17544328

Group type: EXPERIMENTAL
Intervention: Sports drinks (three commercially available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 16883904

Group type: EXPERIMENTAL
Intervention: Bushen Qiangji Granule (BQG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Combined treatment (BQG + sulfasalazine)
Number of subjects: 68
Study: 14661537

Group type: EXPERIMENTAL
Intervention: Total knee replacement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 15
Study: 11022383

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional handpieces
Number of subjects: 77
Study: 7910472

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (cumulative doses of up to 400 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3540072

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million IU/h)
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 29467024

Group type: EXPERIMENTAL
Intervention: Male synthetic sling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial urinary sphincter (AUS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour urinary pad test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical review
Number of subjects: 0
Study: 26980352

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiated dentin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no surface treatment)
Number of subjects: 30
Study: 26417059

Group type: EXPERIMENTAL
Intervention: Sonolysis
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control
Number of subjects: 242
Study: 24281606

Group type: EXPERIMENTAL
Intervention: Insulin treatment on half of the wound surface
Number of subjects: 8

Group type: COMPARATOR
Intervention: No insulin treatment on the other half of the wound surface
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: No insulin treatment
Number of subjects: 8
Study: 21364488

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 82
Study: 19850735

Group type: EXPERIMENTAL
Intervention: exercise + fortified milk
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: fortified milk
Number of subjects: 180

Group type: COMPARATOR
Intervention: control
Number of subjects: 180
Study: 17148968

Group type: EXPERIMENTAL
Intervention: Generic formulation of stavudine (40 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Generic formulation of lamivudine (150 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Generic formulation of nevirapine (200 mg twice daily)
Number of subjects: 12
Study: 14982247

Group type: EXPERIMENTAL
Intervention: Reading with Phoneme
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Reading with Rhyme and Phoneme
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Reading with Rhyme
Number of subjects: 410

Group type: COMPARATOR
Intervention: Taught control condition (Reading)
Number of subjects: 410
Study: 11682370

Group type: EXPERIMENTAL
Intervention: Early enrollment (first-month accrual)
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Relative enrollment during the first month over target sample size
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Masking (double-blind vs. single or unblinded studies)
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Rapid early accrual (additional patients accrued in the first month)
Number of subjects: 28992

Group type: EXPERIMENTAL
Intervention: Statistical significance in favor of an experimental arm
Number of subjects: 28992
Study: 9022561

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Stress management
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Supplementation with calcium
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Supplementation with magnesium
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Supplementation with potassium
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Supplementation with fish oil
Number of subjects: 2182
Study: 7633298

Group type: EXPERIMENTAL
Intervention: Letter sent to group E patients suggesting they make an appointment with a physician specializing in alcoholism.
Number of subjects: 362

Group type: COMPARATOR
Intervention: No letter sent to group C patients.
Number of subjects: 362
Study: 2701324

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment Program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methadone patients receiving additional medication for cocaine dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient treatment (28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient treatment (day hospital or behavioral treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 0
Study: 302028

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoprenaline inhalation test
Number of subjects: 20
Study: 30630461

Group type: EXPERIMENTAL
Intervention: Placebo (deliberate positive information)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard information (water)
Number of subjects: 24
Study: 29179766

Group type: EXPERIMENTAL
Intervention: Water treadmill at stifle height and 1.39 m/s
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Water treadmill at carpus height and 1.39 m/s
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dry treadmill (control) at all three speeds
Number of subjects: 15
Study: 25917730

Group type: EXPERIMENTAL
Intervention: Superior hypogastric plexus neurolysis (SHN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bladder hydrodistention (HD)
Number of subjects: 24
Study: 23692260

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate or olmesartan medoxomil (antihypertensive treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 44
Study: 21745623

Group type: EXPERIMENTAL
Intervention: BTE (333 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (powdered barley tea)
Number of subjects: 36
Study: 19563637

Group type: EXPERIMENTAL
Intervention: Non-invasive biomarkers of airway inflammation and early lung function measurements
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Repeated measurements of lung function tests and inflammatory markers in exhaled breath, blood, and faeces
Number of subjects: 250

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 250
Study: 16998649

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 to 12 mg per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14967982

Group type: EXPERIMENTAL
Intervention: Same-day scheduling
Number of subjects: 0
Study: 11096003

Group type: EXPERIMENTAL
Intervention: Levofloxacin treatment
Number of subjects: 535

Group type: COMPARATOR
Intervention: Antibiotic therapy (not specified)
Number of subjects: 535
Study: 9282188

Group type: EXPERIMENTAL
Intervention: QuickCast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional short-arm fibreglass tape cast
Number of subjects: 30
Study: 8352621

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz) at 10 to 12 J/cm2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz) at 6, 8, 10, or 12 J/cm2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm)
Number of subjects: 25
Study: 3304950

Group type: EXPERIMENTAL
Intervention: cyclandelate 800 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: flunarizine 5 mg daily
Number of subjects: 40
Study: 29880288

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 10615

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 10615
Study: 27823681

Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg daily
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Clopidogrel 75mg daily
Number of subjects: 2000
Study: 24602602

Group type: EXPERIMENTAL
Intervention: 5-day course of amoxicillin/clavulanic acid 625 mg orally 8-hourly for 4 days after initial intravenous treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously followed by placebo orally
Number of subjects: 94